GLP-1s for Adults Under 35: What to Know

If you’re in your 20s or early 30s, some of your questions about GLP-1 medications may be different from an older adult’s. You may be looking at many more years ahead, a first real budget, and decisions about starting a family. This page covers what’s worth knowing before you talk to a clinician.

Why interest is growing

GLP-1 use has grown quickly across the U.S. adult population. In a November 2025 KFF poll, 12% of adults said they were currently taking a GLP-1, up 6 percentage points from May 2024. Telehealth has also made these programs easier to find, and they get a lot of attention online.

Younger adults are still a small part of that picture. In the same poll, 4% of adults ages 18–29 said they currently use a GLP-1, compared with 22% of adults ages 50–64. We did not find strong research focused specifically on adults under 35, so much of what follows comes from studies of adults overall. Your experience may differ from those averages.

Eligibility is the same at any adult age

There is no separate standard for younger adults. The labeling for semaglutide and tirzepatide weight management products describes adults with obesity, or adults with overweight and at least one weight-related condition. The National Institutes of Health gives the same general picture, using BMI thresholds of 30, or 27 with weight-related health problems. The orforglipron (Foundayo) label (PDF) describes the same two groups of adults.

A licensed clinician makes the call, based on your health and history. Being young doesn’t rule you out, and it doesn’t qualify you either. Our guide to how telehealth access works explains the steps and the screening in more detail.

Bring up pregnancy plans early

This is often more relevant to people under 35, so raise it at your first visit.

The semaglutide label says to stop the medication at least 2 months before a planned pregnancy, and when a pregnancy is recognized.
The tirzepatide label says it may reduce how well oral contraceptive pills work. It advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase. It also says to stop when a pregnancy is recognized.
The orforglipron label (PDF) says it may cause fetal harm and should be stopped when a pregnancy is recognized. It advises effective contraception during treatment, and it says orforglipron isn’t recommended while breastfeeding. Tell your provider if you’re pregnant, plan to become pregnant, or plan to breastfeed.

Realistic expectations

Results vary

People respond differently to these medications. Clinical trial numbers are averages from closely managed studies, and individual responses can vary widely. NIH says that if you haven’t lost at least 5% of your starting weight after 12 weeks on the full dose, your clinician will probably advise you to stop. Nobody can promise you a particular outcome.

These are long-term medications

The labels describe use to reduce excess body weight and maintain that reduction long term, alongside a reduced-calorie diet and more physical activity. If a medication is working and you aren’t having serious side effects, NIH says your clinician may advise staying on it indefinitely. That’s worth thinking about at 25, because “long term” may mean something different for you than for someone starting at 55. Side effects also matter over that span, so read our side effects page.

What happens when you stop

NIH says plainly that you probably will regain some weight after stopping. Two trials give a sense of the average pattern:

In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost, on average, one year after stopping.
In SURMOUNT-4, people switched from tirzepatide to placebo gained an average of 14% between weeks 36 and 88, while those who stayed on the medication lost a further 5.5%.

The orforglipron label (PDF) doesn’t include stopping or regain data, so talk to a licensed provider about what to expect.

None of this means you can never stop. It means stopping is worth planning with a clinician, rather than deciding on your own because of a price change or a lapse in coverage. Don’t stop or change a medication without talking to them.

Muscle, protein, and nutrition

When weight goes down, some of it can come from muscle as well as fat. A joint advisory from four professional groups focuses on this. Its emphasis is on staying strong and getting enough nutrition. Your health is the goal here, and it’s much more than a number on a scale.

Protein

The advisory says sufficient dietary protein should be a priority for helping preserve muscle and bone. Appetite can drop on these medications, which can make that harder. Your needs depend on your body and health, so ask a clinician or registered dietitian for a target that fits you.

Strength training

The same advisory says more protein alone is likely inadequate to preserve muscle without structured strength training. The CDC recommends muscle-strengthening activity 2 days a week for all adults, plus 150 minutes of moderate activity. The advisory’s suggestion for people on GLP-1s is higher, at least 3 strength sessions a week. Weights, resistance bands, and bodyweight exercises such as push-ups all count, so you don’t need a gym.

Nutrition basics

When you’re eating less, each meal matters more. The advisory encourages nutrient-dense, minimally processed foods such as fruits, vegetables, whole grains, legumes, lean proteins, nuts, and seeds. It also encourages adequate fluids and fiber. Regular, small meals can help too.

Talking to a clinician

Before your first visit, it can help to write down a few questions:

What would success look like for my health, and how would we measure it?
How long might I stay on this, and what’s the plan if I stop?
What should I change about food and exercise, and can you refer me to a dietitian?
How does this fit with my other medications, birth control, and pregnancy plans?

Cost over time, early in your career

The monthly price is only part of the question. If a medication is long term, the number that matters is what you’ll pay over years, on a budget that may change. In a 2025 KFF poll, 56% of GLP-1 users said the drugs were difficult to afford, and 14% said they had stopped because of the cost.

A few things to think through before you start:

Annualize it. Multiply the full monthly cost by 12, and add program fees, labs, and follow-ups.
Check higher doses. Some prices change as your dose changes, so ask what you’d pay after the first few months.
Stress-test your budget. Would it still work after a job change or a rent increase?
Don’t count on coverage lasting. Young adults often change jobs and plans, and employer coverage varies. KFF found 18% of larger firms covered GLP-1s for weight loss in 2026. Check your plan again at each job change and each open enrollment.
Plan the exit. Since stopping can lead to regain, decide with a clinician what you’d do if you could no longer afford treatment.

See dated numbers and a 12-month example on our costs page, and compare programs on our providers page.

Frequently asked questions

Can you get a GLP-1 in your 20s?

An adult in their 20s can be evaluated the same way as any other adult. A licensed clinician looks at your health, health history, and goals, and then decides whether a medication is appropriate. Age alone does not settle it either way.

Are GLP-1s different for young adults?

The labeling for adults does not set separate rules for people under 35. What often differs is the planning: how many years you might stay on a medication, how pregnancy plans fit in, and how you will pay for it over time.

What happens if I stop taking a GLP-1?

The National Institutes of Health says you will probably regain some weight after stopping weight management medication. Trials of semaglutide and tirzepatide found substantial regain on average after treatment ended. Talk to your clinician before you stop or change a medication.

Do I need to lift weights while taking a GLP-1?

It is not a requirement, but a joint advisory from four professional groups says strength training and enough dietary protein help preserve muscle and bone. The CDC recommends muscle-strengthening activity two days a week for all adults. Ask a clinician what fits your health and fitness level.

Should I tell the clinician if I might want to get pregnant?

Yes. Pregnancy plans matter here. The semaglutide label says to stop at least 2 months before a planned pregnancy, the tirzepatide label covers oral contraceptives and pregnancy, and the orforglipron label says it may make birth control pills work less well. A clinician can explain what applies to you.

More questions? See our full FAQ, or read how GLP-1 telehealth access works.

Sources

We read each of these pages on November 1, 2026. Rules and labeling change, so check the source for the current version.

KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. KFF, November 14, 2025.
2026 Employer Health Benefits Survey. KFF, October 22, 2026.
Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH), last reviewed June 2024.
Semaglutide injection and tablets prescribing information. DailyMed, U.S. National Library of Medicine, revised June 2026.
Tirzepatide injection prescribing information. DailyMed, U.S. National Library of Medicine, revised August 2026.
Orforglipron tablets prescribing information (PDF). Eli Lilly and Company, revised July 2026.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Wilding JPH, et al. Diabetes, Obesity and Metabolism, 2022.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Aronne LJ, et al. JAMA, 2024.
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. Obesity Pillars, 2026.
Adult Activity: An Overview. U.S. Centers for Disease Control and Prevention, December 20, 2023.
What Counts as Physical Activity for Adults. U.S. Centers for Disease Control and Prevention, December 6, 2023.